Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling

Imagem de Miniatura
Arquivos
art_SILVA_Prolactin_Promotes_Breast_Cancer_Cell_Migration_through_Actin_2015.PDF (3.43 MB)
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
AMARAL, Vinicius Cestari do
GABRIELLI, Valentina
GUEVARA, Maria Magdalena Montt
MANNELLA, Paolo
SIMONCINI, Tommaso
Citação
FRONTIERS IN ENDOCRINOLOGY, v.6, article ID 186, 8p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The role of prolactin on breast cancer development and progression is debated. Breast cancer progression largely depends on cell movement and on the ability to remodel the actin cytoskeleton. In this process, actin-binding proteins are requested to achieve fibrillar actin de-polymerization and relocation at the cell membrane. Kinases such as focal adhesion kinase (FAK) are later required to form actin/vinculin-enriched structures called focal adhesion complexes, which mediate firm adhesion to the extracellular matrix. These controllers are regulated by c-Src, which forms multiprotein signaling complexes with membrane receptors and is regulated by a number of hormones, including prolactin. We here show that breast cancer cells exposed to prolactin display an elevated c-Src expression and phosphorylation. In parallel, increased moesin and FAK expression and phosphorylation are found. These molecular changes are associated to relocation to the plasma membrane of cytoskeletal actin fibers and to increased horizontal cell movement. In conclusion, prolactin regulates actin remodeling and enhances breast cancer cell movement. This finding broadens the understanding of prolactin actions on breast cancer cells, highlighting new pathways that may be relevant to on breast cancer progression.
Palavras-chave
T47D, MCF-7, ZR75-1, breast cancer, prolactin, cell migration, actin cytoskeleton
URI
https://observatorio.fm.usp.br/handle/OPI/16248
Referências
  1. Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422
  2. Alowami S, 2003, BREAST CANCER RES, V5, pR129, DOI 10.1186/bcr622
  3. Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257
  4. Barati MT, 2015, CELL SIGNAL, V27, P1178, DOI 10.1016/j.cellsig.2015.02.022
  5. Barcus CE, 2013, J BIOL CHEM, V288, P12722, DOI 10.1074/jbc.M112.447631
  6. Barcus CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116891
  7. Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
  8. Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076
  9. Flamini MI, 2009, J CELL MOL MED, V13, P2396, DOI 10.1111/j.1582-4934.2008.00505.x
  10. Fu XD, 2010, ENDOCR-RELAT CANCER, V17, P431, DOI 10.1677/ERC-09-0258
  11. Fu Xiao-Dong, 2010, Horm Mol Biol Clin Investig, V3, P383, DOI 10.1515/HMBCI.2010.058
  12. Giretti MS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00080
  13. Jacobson EM, 2010, TRENDS ENDOCRIN MET, V21, P691, DOI 10.1016/j.tem.2010.08.004
  14. LaPensee EW, 2009, CARCINOGENESIS, V30, P1298, DOI 10.1093/carcin/bgp120
  15. Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447
  16. McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647
  17. Naderi A, 2015, ADV EXP MED BIOL, V846, P189, DOI 10.1007/978-3-319-12114-7_8
  18. O'Leary KA, 2015, ADV EXP MED BIOL, V846, P201, DOI 10.1007/978-3-319-12114-7_9
  19. Piazza TM, 2009, MOL ENDOCRINOL, V23, P202, DOI 10.1210/me.2008-0341
  20. Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X
  21. Ray S, 2011, J ENDOCRINOL, V208, P21, DOI 10.1677/JOE-10-0137
  22. Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619
  23. Sanchez AM, 2011, MOL HUM REPROD, V17, P219, DOI 10.1093/molehr/gaq097
  24. Sanchez AM, 2010, MOL ENDOCRINOL, V24, P2114, DOI 10.1210/me.2010-0252
  25. Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002
  26. Simoncini T, 2000, NATURE, V407, P538
  27. Simoncini T, 2006, MOL ENDOCRINOL, V20, P1756, DOI 10.1210/me.2005-0259
  28. Swaminathan G, 2008, J MAMMARY GLAND BIOL, V13, P81, DOI 10.1007/s10911-008-9068-6
  29. Taliaferro-Smith L, 2015, ONCOTARGET, V7, P4757, DOI 10.18632/oncotarget.3023
  30. Thamilselvan V, 2007, FASEB J, V21, P1730, DOI 10.1096/fj.06-6545
  31. Tworoger SS, 2008, J MAMMARY GLAND BIOL, V13, P41, DOI 10.1007/s10911-008-9063-y
  32. Tworoger SS, 2007, J CLIN ONCOL, V25, P1482, DOI 10.1200/JCO.2006.07.6356
  33. Tworoger SS, 2013, CANCER RES, V73, P4810, DOI 10.1158/0008-5472.CAN-13-0665
  34. Vara JAF, 2001, MOL BIOL CELL, V12, P2171
  35. Zhang C, 2015, MOL CELL ENDOCRINOL, V401, P173, DOI 10.1016/j.mce.2014.12.006
  36. Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136
  37. Zinger M, 2003, J CLIN ENDOCR METAB, V88, P689, DOI 10.1210/jc.2002-021255

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03